Sumitomo Pharma
4506.TApprovedSumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
4506.T · Stock Price
Historical price data
AI Company Overview
Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
Technology Platform
The company leverages traditional small-molecule drug discovery alongside strategic platforms in gene therapy and targeted oncology, focusing on novel mechanisms in CNS and acquired biologics capabilities.
Pipeline Snapshot
279279 drugs in pipeline, 109 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Lunesta + Placebo control | Obstructive Sleep Apnea | Approved |
| Nebulized arformoterol + Salmeterol | Chronic Obstructive Pulmonary Disease | Approved |
| eszopiclone, zolpidem, placebo | Healthy | Approved |
| nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose... | Mucociliary Clearance | Approved |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone tre... | Generalized Anxiety Disorder | Approved |
FDA Approved Drugs
5Opportunities
Risk Factors
Competitive Landscape
Sumitomo Pharma competes with global pharma giants like Johnson & Johnson and Otsuka in psychiatry, AbbVie in women's health, and AstraZeneca in oncology. Its differentiation strategy relies on developing novel mechanisms of action (e.g., TAAR1 agonism), focusing on specialized, high-unmet-need patient populations, and leveraging strategic partnerships to augment its R&D and commercial reach.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile